6,118 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Thematics Asset Management

Thematics Asset Management purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 6,118 shares of the biopharmaceutical company’s stock, valued at approximately $1,995,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of ALNY. Atlantic Union Bankshares Corp purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth $30,000. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Elevation Point Wealth Partners LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $37,000. Ameritas Advisory Services LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $42,000. Finally, AlphaQuest LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $43,000. 92.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Barclays lifted their target price on Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. The Goldman Sachs Group increased their price target on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Truist Financial boosted their target price on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Royal Bank Of Canada raised their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Twenty-three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $482.17.

Alnylam Pharmaceuticals Trading Down 6.1%

NASDAQ ALNY opened at $430.02 on Tuesday. The firm has a 50 day simple moving average of $456.43 and a 200-day simple moving average of $404.78. The firm has a market cap of $56.81 billion, a price-to-earnings ratio of 1,791.75 and a beta of 0.30. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 10,000 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total value of $4,512,700.00. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,517,119.43. This represents a 13.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 60,328 shares of company stock worth $27,288,993. 1.20% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.